Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016

  • ID: 3802757
  • Report
  • 70 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • LG Life Science LTD.
  • Pharmedartis GmbH
  • MORE
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016

Summary

‘Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016’, provides in depth analysis on Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted pipeline therapeutics.

The report provides comprehensive information on the Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62)
- The report reviews Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics and enlists all their major and minor projects
- The report assesses Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • LG Life Science LTD.
  • Pharmedartis GmbH
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Overview

Therapeutics Development

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Products under Development by Stage of Development

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Products under Development by Therapy Area

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Products under Development by Indication

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Products under Development by Companies

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Products under Development by Universities/Institutes

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Companies Involved in Therapeutics Development

Bellicum Pharmaceuticals, Inc.

Conatus Pharmaceuticals Inc.

LG Life Science LTD.

Novelix Pharmaceuticals, Inc.

Pharmedartis GmbH

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Drug Profiles

BPX-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flavokawain A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granzyme B/VEGF - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HaA-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivocasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVX-207 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plinabulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate CASP3 and CASP9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Caspase 8, 9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Dormant Projects

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Discontinued Products

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Featured News & Press Releases

May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication

May 19, 2016: Bellicum Announces Data Presentation of BPX-501 at the European Hematology Association

May 12, 2016: BeyondSpring Chief Medical Officer Served as Panelist at NewYorkBIO

May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial

Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data

Apr 05, 2016: Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Updates

Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting

Feb 24, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin at 4th Annual Cancer Biopartnering & Investment Forum in NYC

Feb 22, 2016: FDA Grants Orphan Drug Designation to Bellicum’s BPX-501 for the Treatment of Immunodeficiency and GvHD Following Stem Cell Transplant

Feb 08, 2016: BeyondSpring Pharmaceuticals’ Data Indicating Plinabulin Enhances Immune Response Provides Basis for Planned Phase I/II Combination Trial in NSCLC

Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis

Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis

Jan 07, 2016: BeyondSpring Pharmaceuticals to Present at 8th Annual Biotech Showcase

Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

Jan 05, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin-Immune System Interactions at AACR’s 2016 Tumor Microenvironment Special Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 70List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016

Pipeline by Conatus Pharmaceuticals Inc., H1 2016

Pipeline by LG Life Science LTD., H1 2016

Pipeline by Novelix Pharmaceuticals, Inc., H1 2016

Pipeline by Pharmedartis GmbH, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016 54List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • LG Life Science LTD.
  • Pharmedartis GmbH
  • MORE
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Caspase 9 - Pipeline Review, H1 2016, outlays comprehensive information on the Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Caspase-9 is an initiator caspase encoded by the CASP9 gene. Binding of caspase-9 to Apaf-1 leads to activation of the protease which cleaves and activates caspase-3. It is involved in the activation cascade of caspases responsible for apoptosis execution. It promotes DNA damage-induced apoptosis in an ABL1/c-Abl-dependent manner. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Furthermore, this report also reviews key players involved in Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Bellicum Pharmaceuticals, Inc.
Conatus Pharmaceuticals Inc.
LG Life Science LTD.
Novelix Pharmaceuticals, Inc.
Pharmedartis GmbH
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll